US Bancorp’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

US Bancorp’s Portfolio ZYNE Stock Details ZYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-100	Closed	-$1K	–	3754
2019 Q3	$1K	Hold	100	–	–	﹤0.01%	3533
2019 Q2	$1K	Hold	100	–	–	﹤0.01%	3581
2019 Q1	$1K	Hold	100	–	–	﹤0.01%	3540
2018 Q4	$0	Hold	100	–	–	﹤0.01%	3728
2018 Q3	$1K	Buy	+100	New	+$768	﹤0.01%	3594

Other funds holding ZYNE

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ZCA

Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

US Bancorp's ZYNE Position: Q4 2019 in Review

US Bancorp sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2019, closing a stake of 100 shares — an estimated $1K sold.

US Bancorp first reported a position in ZYNE in Q3 2018 and held it in 5 quarters. The position peaked at $1K in Q3 2019. 79 funds tracked by Wall St. Rank hold ZYNE as of Q4 2019.

US Bancorp reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2019 after selling out during the quarter.
US Bancorp sold 100 Zynerba Pharmaceuticals, Inc shares in Q4 2019, an estimated $1K.
US Bancorp first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2018 and held it in 5 quarters.
US Bancorp's Zynerba Pharmaceuticals, Inc position peaked at $1K in Q3 2019.
79 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2019.

Based on US Bancorp's 13F filing for Q4 2019, filed 4 Feb 2020.